购物车
- 全部删除
- 您的购物车当前为空
NQ301 是一种抗血栓剂,能够抑制胶原蛋白激发的兔血小板聚集,IC50=10 mg/mL。
为众多的药物研发团队赋能,
让新药发现更简单!
NQ301 是一种抗血栓剂,能够抑制胶原蛋白激发的兔血小板聚集,IC50=10 mg/mL。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 225 | 现货 | |
5 mg | ¥ 498 | 现货 | |
10 mg | ¥ 747 | 现货 | |
25 mg | ¥ 1,250 | 现货 | |
50 mg | ¥ 1,930 | 现货 | |
100 mg | ¥ 2,880 | 现货 | |
500 mg | ¥ 6,580 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 548 | 现货 |
产品描述 | NQ301, an antithrombotic agent, inhibits collagen-challenged rabbit platelet aggregation (IC50: 10 mg/mL). |
靶点活性 | Platelet aggregation (rabbit, collagen-challenged):10 mg/mL |
体外活性 | NQ301 dose-dependently inhibits collagen (10 mg/mL, IC50: 0.60±0.02 μM), U46619 (1 mg/mL, IC50: 0.58±0.04 μM) and arachidonic acid (100 mg/mL, IC50: 0.78±0.04 μM) challenged rabbit platelet aggregation. NQ301 potently suppresses thromboxane B2 formation by platelets that are exposed to arachidonic acid in a concentration-dependent manner, but had no effect on the production of prostaglandin D2, indicating an inhibitory effect on thromboxane A2 synthase. NQ301 markedly inhibits the increase of cytosolic Ca2+ concentration and ATP secretion, and also markedly increases platelet cAMP levels in the activated platelets. The antiplatelet activity of NQ301 may be mediated by inhibition of cytosolic Ca2+ mobilization, enhancement of cAMP production and inhibition of ATP secretion in activated platelets. |
激酶实验 | Compounds are dissolved in DMSO (5 mg/mL) and diluted with PBS/EtOH (70:30).Kinetic analyses are carried out for TB5 and TB8. A set of Lineweaver–Burk plots are constructed in the absence and presence of various concentrations of compounds TB5 and TC8. The set consists of five graphs, each constructed by measuring MAO-B and MAO-A catalytic rates at different substrate concentrations (0.1-1 μM). The first Lineweaver–Burk plot is constructed in the absence of inhibitor, while the remaining four graphs are constructed in the presence of different concentrations of TB5 and TB8[1]. |
细胞实验 | ished rabbit platelet suspension is challenged by addition of collagen (10 mg/mL), arachidonic acid (100 μM) or U46619 (1 μM). Concentration- response relationship is determined in the absence or presence of a range of concentrations of NQ301 (0, 0.25, 0.5, 0.75, 1 μM); aspirin-treated platelets (50 μM for 5 min) are used to prevent any possible contribution of endogenous arachidonic acid metabolites to platelet aggregation. The resulting aggregation, measured as the change in light transmission, is recorded for 5 min. The extent of platelet aggregation is expressed as % of the control[1]. |
分子量 | 325.75 |
分子式 | C18H12ClNO3 |
CAS No. | 130089-98-4 |
Smiles | CC(=O)c1ccc(NC2=C(Cl)C(=O)c3ccccc3C2=O)cc1 |
密度 | 1.40 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
溶解度信息 | DMSO: 6.88 mg/mL (21.11 mM), Sonication is recommended. | |||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容